This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Strickberger, S. A. Search for Related Content PubMed PubMed Citation Articles by Strickberger, S. A.

Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemicdilated cardiomyopathy and asymptomaticnonsustained ventricular tachycardia—AMIOVIRT

S. Adam Strickberger, MD, FACC^*,*, John D. Hummel, MD, FACC, Thomas G. Bartlett, MD, FACC, Howard I. Frumin, MD, FACC, Claudio D. Schuger, MD, FACC^||, Scott L. Beau, MD, FACC^¶, Cynthia Bitar, RN^#, Fred Morady, MD, FACC^# AMIOVIRT Investigators

^* Washington Hospital Center, Washington, DC, USA
Mid-Ohio Cardiology Consultants, Columbus, Ohio, USA
Northwest Ohio Cardiology Consultants, Toledo, Ohio, USA
Northpointe Heart Center, Berkley, Michigan, USA
^|| Henry Ford Hospital, Detroit, Michigan, USA
^¶ Blandford Physician Center, Little Rock, Arkansas, USA
^# University of Michigan, Ann Arbor, Michigan, USA

View larger version (13K): [in a new window]   Figure 1 Kaplan-Meier estimates of cumulative survival among patients treated with amiodarone (solid line) or an implantable defibrillator (dotted line).

View larger version (14K): [in a new window]   Figure 2 Kaplan-Meier estimates of arrhythmia-free survival among patients treated with amiodarone (solid line) or an implantable cardioverter-defibrillator (dotted line).